血漿蛋白治療市場規模、佔有率和成長分析：按產品類型、應用、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球血漿蛋白治療市場價值為 295 億美元，預計到 2025 年將成長至 314.2 億美元，到 2033 年將成長至 520 億美元，在預測期（2026-2033 年）內複合年成長率為 6.5%。

全球血漿蛋白治療市場的主要驅動力是臨床上對替代療法和免疫調節療法日益成長的需求，這些療法對於治療原發性免疫力缺乏疾病和出血性疾病至關重要。血漿分離技術的進步和血漿採集基礎設施的完善推動了這一發展，提高了血漿的可及性和產量。血漿供應的穩定性影響著產量、價格和市場覆蓋範圍。捐贈者招募和血漿分離能力的提升使製造商能夠擴大生產規模，從而降低成本並提高可及性，尤其是在中等收入地區。此外，人工智慧在捐贈者篩檢和生產流程中的應用提高了捐贈者配對的準確性，加快了蛋白質設計，並最佳化了品管，從而改善了患者的治療效果。這使得應對複雜的供應情況和高臨床需求成為可能。

全球血漿蛋白治療市場的成長要素

全球血漿蛋白療法市場的主要促進因素是慢性病和遺傳性疾病（例如血友病、免疫力缺乏和自體免疫疾病）盛行率的不斷上升。隨著人們對這些疾病的認知不斷提高，對源自人類血漿的有效治療方法的需求也日益成長。此外，技術和研究的進步正在拓展血漿蛋白的治療應用，並帶來更廣泛的治療選擇。人口老化也是推動此趨勢的重要因素。老年人通常需要更多的醫療干預，從而增加了對血漿蛋白療法的整體需求，進而推動了該領域的市場成長和創新。

全球血漿蛋白治療市場的限制因素

全球血漿蛋白療法市場的主要限制因素之一是其研發和生產高成本。分離血漿蛋白所需的複雜萃取和純化製程需要先進的技術和專門的設備，從而推高了生產成本。此外，嚴格的監管要求也構成了一項挑戰，因為企業必須經過漫長的核准流程才能確保產品的安全性和有效性。這些經濟負擔會限制研發投入，阻礙創新，並可能限制新治療方法的普及。這種情況最終可能會限制患者獲得必要的血漿蛋白療法。

全球血漿蛋白治療市場趨勢

全球血漿蛋白療法市場正呈現出顯著的治療適應症拓展趨勢，這主要得益於生物學認知的不斷深入，從而發現了新的標靶和患者群。這一發展趨勢推動了製造商和臨床醫生之間的合作，旨在擴大適應症範圍、開發聯合治療，並實施針對各種疾病（包括自體免疫疾病、神經系統疾病和罕見疾病）的個人化給藥策略。這些努力促進了差異化產品策略的形成，並加強了與專家的合作，同時也催生了對全面市場進入計畫的需求。這種轉變正在推動對臨床證據的投入，並建構特異性疾病的價值提案，最終帶來更廣泛的治療選擇和更佳的患者療效。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球血漿蛋白療法市場規模：依產品類型分類

• 免疫球蛋白
• 凝血因子
• 白蛋白
• α-1抗胰蛋白酶抑制劑
• 其他

全球血漿蛋白療法市場規模：按應用領域分類

• 免疫不全症
• 血友病
• 神經病變
• 肝病
• 呼吸系統疾病
• 其他

全球血漿蛋白療法市場規模：依給藥途徑分類

• 靜脈
• 皮下

全球血漿蛋白療法市場規模：按分銷管道分類

• 醫院
• 專科診所
• 零售藥房
• 網路藥房

全球血漿蛋白療法市場規模：依最終用戶分類

• 醫院
• 門診手術中心
• 專業醫療中心
• 居家醫療

全球血漿蛋白療法市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• CSL Behring
• Takeda Pharmaceutical Company
• Grifols
• Kedrion Biopharma
• Octapharma
• ADMA Biologics
• China Biologic Products Holdings
• GC Biopharma
• Biotest
• LFB Group
• Emergent BioSolutions
• Bharat Serums and Vaccines
• Intas Pharmaceuticals
• Shire Human Genetic Therapies
• Kamada
• PlasmaGen BioSciences
• Hualan Biological Engineering
• Sanquin Plasma Products
• Shanghai RAAS Blood Products
• Bio Products Laboratory

結論與建議

Global Plasma Protein Therapeutic Market size was valued at USD 29.5 Billion in 2024 and is poised to grow from USD 31.42 Billion in 2025 to USD 52.0 Billion by 2033, growing at a CAGR of 6.5% during the forecast period (2026-2033).

The global plasma protein therapeutics market is significantly driven by the rising clinical need for replacement and immunomodulatory therapies, which are crucial for treating conditions like primary immunodeficiency and bleeding disorders. The sector's evolution has been supported by advancements in fractionation technologies and enhanced plasma collection infrastructures, facilitating greater accessibility and yield. The resilience of plasma supply influences production volume, pricing, and market reach; increased donor recruitment and fractionation capacity enable manufacturers to scale outputs, reducing costs and expanding access, especially in middle-income regions. Additionally, the integration of AI into donor screening and manufacturing processes is improving patient outcomes by enhancing donor matching, accelerating protein design, and optimizing quality control, thereby addressing the complexities of supply and high clinical demands more effectively.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Plasma Protein Therapeutic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Plasma Protein Therapeutic Market Segments Analysis

Global plasma protein therapeutic market is segmented by product type, application, route of administration, distribution channel, end user and region. Based on product type, the market is segmented into Immunoglobulins, Coagulation Factors, Albumin, Alpha-1 Proteinase Inhibitors and Others. Based on application, the market is segmented into Immunodeficiency Diseases, Hemophilia, Neurological Disorders, Liver Diseases, Pulmonary Disorders and Others. Based on route of administration, the market is segmented into Intravenous and Subcutaneous. Based on distribution channel, the market is segmented into Hospitals, Specialty Clinics, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Ambulatory Surgical Centers, Specialty Care Centers and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Plasma Protein Therapeutic Market

A key market driver for the global plasma protein therapeutic market is the increasing prevalence of chronic and genetic disorders, such as hemophilia, immunodeficiencies, and autoimmune diseases. As awareness of these conditions grows, the demand for effective therapies derived from human plasma is rising. Additionally, advancements in technology and research are expanding the therapeutic applications of plasma proteins, resulting in enhanced treatment options. The aging population further contributes to this trend, as older individuals typically require more medical interventions, boosting the overall demand for plasma protein therapies, thereby propelling market growth and innovation within the sector.

Restraints in the Global Plasma Protein Therapeutic Market

One key market restraint for the global plasma protein therapeutic market is the high cost associated with the development and manufacturing of these therapies. The complex extraction and purification processes required to isolate plasma proteins demand advanced technology and specialized facilities, driving up production expenses. Furthermore, stringent regulatory requirements pose additional challenges, as companies must navigate lengthy approval processes to ensure product safety and efficacy. The financial burden can limit investment in research and development, thereby hindering innovation and limiting the availability of new therapies. This dynamic can ultimately restrict patient access to essential plasma protein treatments.

Market Trends of the Global Plasma Protein Therapeutic Market

The Global Plasma Protein Therapeutic market is witnessing a significant trend towards the expansion of therapeutic indications, driven by enhanced biological insights that identify new targets and patient populations. This evolution is prompting manufacturers and clinicians to collaborate on label expansions, develop combination therapies, and implement personalized dosing strategies tailored to a variety of conditions, including autoimmune, neurological, and rare diseases. Such initiatives foster differentiated product strategies and strengthen specialist engagement, while also necessitating comprehensive market access planning. This shift encourages investments in clinical evidence generation and the creation of disease-specific value propositions, ultimately broadening treatment options and enhancing patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Plasma Protein Therapeutic Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Immunoglobulins
• Coagulation Factors
• Albumin
• Alpha-1 Proteinase Inhibitors
• Others

Global Plasma Protein Therapeutic Market Size by Application & CAGR (2026-2033)

• Market Overview
• Immunodeficiency Diseases
• Hemophilia
• Neurological Disorders
• Liver Diseases
• Pulmonary Disorders
• Others

Global Plasma Protein Therapeutic Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Subcutaneous

Global Plasma Protein Therapeutic Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Online Pharmacies

Global Plasma Protein Therapeutic Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Specialty Care Centers
• Homecare Settings

Global Plasma Protein Therapeutic Market Size & CAGR (2026-2033)

• North America (Product Type, Application, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Product Type, Application, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADMA Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GC Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Serums and Vaccines
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire Human Genetic Therapies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PlasmaGen BioSciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanquin Plasma Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations